|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
TCTR |
|
Last refreshed on:
|
1 April 2024 |
|
Main ID: |
TCTR20140901001 |
|
Date of registration:
|
01/09/2014 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Use of brain perfusion SPECT to determine responder to choline esterase inhibitor to reduce national therapeutic cost
|
|
Scientific title:
|
Use of brain perfusion SPECT to determine responder to choline esterase inhibitor to reduce national therapeutic cost |
|
Date of first enrolment:
|
01/05/2014 |
|
Target sample size:
|
|
|
Recruitment status: |
Completed |
|
URL:
|
https://www.thaiclinicaltrials.org/show/TCTR20140901001 |
|
Study type:
|
Observational |
|
Study design:
|
N/A
|
|
Phase:
|
Phase 4
|
|
|
Countries of recruitment
|
|
THAILAND
| | | | | | | |
|
Contacts
|
|
Name:
|
Supatporn
Tepmongkol |
|
Address:
|
Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chulalongkorn University
10330
Bangkok
Thailand |
|
Telephone:
|
022564283 |
|
Email:
|
supatporn@hotmail.com |
|
Affiliation:
|
Faculty of Medicine, Chulalongkorn University |
|
|
Name:
|
Supatporn
Tepmongkol |
|
Address:
|
Division of Nuclear Medicine, Department of Radiology, Faculty of Medicine, Chulalongkorn University
10330
Bangkok
Thailand |
|
Telephone:
|
022564283 |
|
Email:
|
supatporn@hotmail.com |
|
Affiliation:
|
Faculty of Medicine, Chulalongkorn University |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: Diagnosis of probable Alzheimer's disease by NINCDS/ADRDA criteria, mild to moderate degree
Exclusion criteria: Severe head trauma, delirium, depression, other known neuro-psychologic diseases, COPD, asthma, sik sinus syndrome, ischemic heart disease, peptic ulcer, history of gastrointestinal bleeding, type I DM, had received choline esterase inhibitors or nicergoline or other research drugs within 1 month before the study, alcohol or drug abuse, during treatment with NSAIDs, anticholinergic, carrbamazepine, dexamethasone, phenobarbital, ketoconazole
Age minimum:
50 Years
Age maximum:
0 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Alzheimer's disease
|
Alzheimer's disease response to donepezil
Alzheimer's disease
|
|
Intervention(s)
|
|
|
|
Screening
|
|
mild to moderate Alzheimer's disease
|
|
Primary Outcome(s)
|
|
cognitive function 0,3,6 months cognitive battery tests
|
|
Secondary Outcome(s)
|
|
brain perfusion SPECT change 0,4 hr, 15 days, 3 months brain perfusion SPECT
|
|
Source(s) of Monetary Support
|
|
government
|
|
Ethics review
|
Status:
Approval date:
Contact:
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
01/09/2014 |
|
URL:
|
|
|
|